Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Operating Leases (2022 - 2026)

Cytek Biosciences filings provide 4 years of Operating Leases readings, the most recent being $14.0 million for Q4 2025.

  • On a quarterly basis, Operating Leases rose 85.94% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 85.94% increase, with the full-year FY2025 number at $14.0 million, up 85.94% from a year prior.
  • Operating Leases hit $14.0 million in Q4 2025 for Cytek Biosciences, down from $16.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $17.4 million in Q2 2025 to a low of $7.4 million in Q1 2025.
  • Median Operating Leases over the past 4 years was $11.2 million (2023), compared with a mean of $11.6 million.
  • Biggest five-year swings in Operating Leases: tumbled 37.81% in 2023 and later skyrocketed 113.85% in 2025.
  • Cytek Biosciences' Operating Leases stood at $15.2 million in 2022, then tumbled by 37.81% to $9.5 million in 2023, then dropped by 20.33% to $7.6 million in 2024, then soared by 85.94% to $14.0 million in 2025.
  • The last three reported values for Operating Leases were $14.0 million (Q4 2025), $16.6 million (Q3 2025), and $17.4 million (Q2 2025) per Business Quant data.